Renal tubular damage: An extraintestinal manifestation of chronic inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 5, 1996, Pages 461-468

  Kreisel, Wolfgang ^a   Wolf, Lothar M ^a   Grotz, Wolfgang ^b   Grieshaber, Margarethe ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Abteilung Nephrologie   (Germany)

Author keywords

5 aminosalicylic acid; Crohn's disease; Enzymuria; Extraintestinal manifestation; Sulphasalazine; Tubulotoxicity; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CREATININE; DIPEPTIDYL PEPTIDASE IV; MARKER; MESALAZINE; MICROSOMAL AMINOPEPTIDASE; N ACETYL BETA GLUCOSAMINIDASE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROHN DISEASE; DISEASE COURSE; ENTERITIS; ENZYMURIA; FEMALE; HUMAN; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; NORMAL VALUE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME TESTS; ENZYMES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; KIDNEY TUBULES; MALE; MESALAMINE; MIDDLE AGED; SULFASALAZINE;

EID: 0029894367     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Lichtenstein GR: Medical therapies for inflammatory bowel disease. Curr Opinion Gastroenterol 1994, 10:390-403.
2. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA, and the Pentasa Crohn's Disease Compassionate Use Study Group: Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Am J Gastroenterol 1993, 88:1343-1351.
3. Steinhart AH, Hemphill D, Greenber GR: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994, 89:2116-2124.
4. Williams CN: Overview of 5-ASA in therapy of inflammatory bowel disease. Can J Gastroenterol 1994, 8:379-382.
5. Cohen RD, Hanauer SB: Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr Opinion Gastroenterol 1995, 11:321-330.
6. Randall RE: Renal failure following antibiotics. Ann Intern Med 1967, 66:1052-1053.
7. Calder IC, Funder CC, Green CR, Ham KN, Tange JD: Nephrotoxic lesions from 5-aminosalicylic acid. BMJ 1972, 1:52-54.
8. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG: Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology 1978, 75:95-99.
9. Novis BH, Korzets Z, Chen P, Bernheim J: Nephrotic syndrome after treatment with 5-aminosalicylic acid. BMJ 1988, 296:1442.
10. Larchet M, Guillot M, Manard JC, Boutard P, Alibert L, Delmas P, Duhamel JF: Enterite de Crohn et nephropathie tubulo-interstitielle chronique chez un adolescent. Arch Fr Pediatr 1988, 45:694-651.
11. von Mühlendahl KE: Nephritis durch 5-Aminosalicylsäure. Dtsch med Wochenschr 1989, 114:236.
12. Ruf-Ballauf W, Hofstädter F, Krentz K: Akute interstitielle Nephritis durch 5-Aminosalicylsäure? Internist 1989, 30:262-264.
13. Henning HV, Meinhold J, Eisenhauer T, Scheler F, Gröne HJ: Chronische interstitielle Nephritis nach Behandlung mit 5-Aminosalicylsäure. Dtsch med Wochenschr 1989, 114:1091.
14. Barbour VM, Williams PF: Nephrotic syndrome associated with sulphasalazine. BMJ 1990, 301: 818.
15. Mehta RP: Acute interstitial nephritis due to 5-aminosalicylic acid. Can Med Assoc J 1990, 143:1031-1032.
16. Behrens R, Ruder H: Chronisch-entzündliche Darmerkrankung und Nephritis. Klin Pädiatr 1992, 204:61-64.
17. Dwarakanath AD, Michael J, Allan RN: Sulphasalazine induced renal failure. Gut 1992, 33:1006-1007.
18. Masson EA, Rhodes JM: Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992, 33:563-564.
19. Thuluvath PJ, Ninkovic M, Calam J, Anderson M: Mesalazine induced interstitial nephritis. Gut 1994, 35:1493-1496.
20. Smilde TJ, vam Liebergen FJHM, Koolen MI, Gerlag PGG, Assmann KJM, Berden JHM: Tubulo-interstiele nefritis door mesalazine (5-ASA)-preparaten. Ned Tijdschr Geneeskd 1994, 138:2557-2561.
21. Witte T, Olbricht CJ, Koch KM: Interstitial nephritis associated with 5-aminosalicylic acid. Nephron 1994, 67:481-482.
22. Colombel JF, Brabant G, Gubler MC, Locquet A, Comes MC, Mahennault M, Delcroix M: Renal insufficience in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994, 344:620-621.
23. Schreiber S, Raedler A, Howaldt S, Zehnter W, Daerr W, Kruis W: 5-Aminosalicylate related renal dysfunction in IBD [abstract]. Gastroenterology 1994, 106:A770.
24. Scherberich JE: Urinary proteins of tubular origin: Basic immunological and clinical aspects. Am J Nephrol 1990, 10 (suppl 1):43-51.
25. Jung K: Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction. Kidney Int 1994, 46 (suppl 47):S29-33.
26. Scherberich JE, Wolf G: Disintegration and recovery of kidney membrane proteins: consequence of acute and chronic renal failure. Kidney Int 1994, 46 (suppl 47):S52-S57.
27. Kreisel W, Heussner R, Volk BA, Büchsel R, Reutter W, Gerok W: Identification of the 110000 Mr glycoprotein isolated from rat liver plasma membrane as dipeptidylaminopeptidase IV. FEBS Lett 1982, 147:85-88.
28. Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn's disease activity index. National Cooperative Crohn's disease study. Gastroenterology 1976, 70:439-444.
29. Rachmilewitz D, on behalf of an international study group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
30. Levine ML: Patterns of tubulo-interstitial damage associated with nonsteroidal anti-inflammatory drugs [review]. Semin Nephrol 1988, 8:55-61.
31. Goebell H, Klotz U, Nehlsen B, Layer P: Release of 5-aminosalicylic acid into the human duodenal, jejunal and ileal lumen from a slow-release preparation. Gut 1993, 34:669-675.
32. Diener U, Tuczek HV, Fischer C, Maier K, Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Arch Pharmacol 1984, 326:278-282.
33. Chapin LE, Soudamore HH, Baggenstoss AH, Bargen JA: Regional enteritis: associated visceral changes. Gastroenterology 1956, 30:404-415.
34. Rovenskaya NM: Morphological changes in the kidneys in nonspecific ulcerative colitis. Arch Pathol 1979, 41:35-39.
35. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA: Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988, 29:669-674.
36. Riley SA, Lloyd DR, Mani V: Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992, 33:1348-1352.
37. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL, and the Pentasa Crohn's Disease Study Group: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993, 104:1293-1301.
38. Bjarnason I, MacPherson AJ: Delivery, safety and efficacy of 5-aminosalicylate preparations. Inflammopharmacology 1993, 2:277-287.
39. Hanauer SB: Aminosalicylate therapy for IBD. In: Inflammatory Bowel Diseases - 1994. Proceedings of the 72nd Falk Symposium held in Strasbourg, France, September 6-8, 1993. D. Rachmilewitz (ed.). Amsterdam: Kluwer Academic, 1994: 192-197.
40. Biddle W, Miner PB: Evaluation of potential nephrotoxicity of oral 5-ASA treatment of patients with ulcerative colitis [abstract]. Gastroenterology 1989, 96:A44.
41. 2 excretion is increased in patients with inflammatory bowel diseases - a new extraintestinal manifestation [abstract]? Gastroenterology 1991, 100:A245.
42. Sninsky C, Hanauer S, Powers B, Robinson M, Mayle J, Elson C, et al.: Sensitive markers of renal dysfunction are elevated in chronic ulcerative colitis [abstract]. World Congress of Gastroenterology, Oct. 1994, A1778 P.
43. Mahmud N, O'Connelle M, Stinson J, Goggins MG, Weir MG, Kelleher D: Tumor necrosis factor-alpha and microalbuminuria in patients with IBD. Eur J Gastroenterol Hepatol 1995, 7:215-219.
44. Stenson WF: Inflammatory mediators in inflammatory bowel disease. Curr Opinion Gastroenterol 1994, 10:384-389.
45. Greenwald BD, James SP: Immunology of inflammatory bowel disease. Curr Opinion Gastroenterol 1995, 11:298-304.
46. Kam L, Pizarro TT, Cominelli F: Cytokines and chemokines in inflammatory bowel disease. Curr Opinion Gastroenterol 1995, 11:305-309.
47. Targan SR, Deem RL, Shanahan F: Role of mucosal T-cell generated cytokines in epithelial cell injury. Immunol Res 1991, 10:472-478.
48. Schreiber S, Heinig T, Panzer U, Teinking R, Bouchard A, Stahl PD, Raedler A: Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995, 108:21-33.
49. Manzano I, Alvarez-Mon M, Vargas JA, Giron JA, Abreu I, Fernandez-Corugedo A, et al: Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients. Gut 1994, 35:955-960.
50. Casini-Raggi V, Kam I, Chong YJT, Fiocchi C, Pizarro TT, Cominelli F: Mucosal imbalance of interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J Immunol 1995, 154:2434-2440.
51. Gross V, Andus T, Daig R, Aschenbrenner E, Falk L, Schölmerich J: Cytokines and cytokine inhibitors in inflammatory bowel disease. Cytokine Congress Reports. 1/94, 25-31. Cytokines and Cytokine Inhibitors in Autoimmune Diseases. 28th Annual Scientific Meeting European Society for Clinical Investigation. Toledo, Spain, 20-23 April 1994.
52. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT: Serum concentration of tumour necrosis factor in childhood chronic inflammatory bowel disease. Gut 1991, 32:913-917.
53. Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, et al.: Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992, 14:451-461.
54. Braegger CP, Nichols S, Murch SH, Stephens S, MacDonald TT: Tumor necrosis factor-α in stool as a marker of intestinal inflammation. Lancet 1992, 339:89-91.
55. Hadziselimovic F, Emmons LR, Gallati H: Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 1995, 37:260-263.
56. Van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's Disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
57. Hommes DW, Radema SA, Jansen J, Smit F, Fockens P, Zhao Y, et al.: Production and cellular source of interleukin-8 in ulcerative colitis. Inflammatory Bowel Diseases 1995, 1:108-116.
58. Klein NJ, Shenan GI, Heyderman RS, Levin M: Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1993, 102:821-832.
59. Murch SH, MacDonald TT, Walter-Smith JA, Levin M, Lionetti P, Klein NJ: Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993, 341:711-714.
60. Yi ES, Ulrich TR: Endotoxin, interleukin-1, and tumour necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 1992, 140:659-663.